Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 15/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 3/20 | 0.39 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445484 | 0.87 | NOD1 (0.46) | NOD1DPP4 | |
| SCHEMBL30591036 | 0.86 | DPP4 (0.52) | NOD1DPP4DPP8DPP9BACE1 | |
| SCHEMBL29630634 | 0.84 | NOD1 (0.52) | NOD1DPP4DPP8DPP9BACE1 | |
| SCHEMBL29777801 | 0.83 | DPP4 (0.52) | NOD1DPP4DPP8DPP9BACE1 | |
| SCHEMBL30525295 | 0.83 | DPP4 (0.55) | NOD1DPP4DPP8DPP9BACE1 | |
| SCHEMBL9347141 | 0.83 | KMT2A (0.52) | NOD1DPP4DPP8DPP9ALOX15 | |
| SCHEMBL29725305 | 0.82 | DPP4 (0.49) | NOD1DPP4DPP8DPP9BACE1 | |
| SCHEMBL11055026 | 0.82 | BACE1 (0.53) | DPP4DPP8DPP9BACE1ALOX15 | |
| SCHEMBL4281665 | 0.82 | NOD1 (0.54) | NOD1DPP4DPP8DPP9BACE1 | |
| SCHEMBL31376471 | 0.82 | NOD1 (0.54) | NOD1DPP4DPP8DPP9BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144613-B2 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20170362626-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20160244798-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2016-08-25 | — | — | US | disclosed |
| EP-2305804-B1 | MonoPEGylated human growth hormone | BOLDER BIOTECHNOLOGY INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8957023-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8932828-B2 | Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins | BOLDER BIOTECHNOLOGY, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130217629-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8288126-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120064573-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-03-15 | — | — | US | disclosed |
| EP-1144613-B1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-1284987-B1 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20050187160-A1 | Monopegylated growth hormone proteins | BOLDER BIOTECHNOLOGY INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050026834-A1 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6753165-B1 | FOR RESIDUES THAT DO NOT FORM DISULFIDE BOND | BOLDER BIOTECHNOLOGY, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20040018586-A1 | Lysis, denaturing, reducing Growth hormones | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1284987-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1144613-A4 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2002-10-29 | — | — | EP | disclosed |
| WO-2001087925-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-1144613-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042175-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC. (US) | 2000-07-20 | — | — | WO | disclosed |